Retinal Surface Macrophage Changes in Thyroid Eye Disease before and after Treatment with Teprotumumab

Figure 1

Pre- and post-teprotumumab evaluation of a patient with thyroid eye disease. (a) and (e) External photos show improvement in orbital congestion after treatment. (b) and (f) Right eye, color fundus pictures show improvement in ONH edema and less congestive vasculature. (c) and (g) Right eye, OCT-scans of the ONH show less edema after treatment. RFNL thickness decreased from 209 μm to 107 μm. (d) and (h) Right eye, central 24-2 Humphrey visual field (HVF). HVF prior to treatment showed central and inferior visual field defects. HVF after 5 infusions of teprotumumab with significant improvement in visual defects.